Vertex's cell therapy gives early hope for weaning some type 1 diabetes patients from insulin
A radical new way of treating type 1 diabetes keeps producing promising early data, raising hopes that a cell therapy might one day become a cure for the disease.
The data, from a small trial, are the most advanced clinical results yet from Vertex Pharmaceuticals’ VX-880 program, which consists of an infusion of lab-grown, insulin-producing cells made from stem cells. Most notably, the newest results include two patients with over a year of follow-up, each of whom have shown significant drops in their A1C blood sugar levels and no severe hypoglycemic events, and remain free from using insulin as of a May data cut-off. Data from three additional patients, who received the therapy more recently, are following a similar trajectory.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
